New radioactive therapy shows promise for Hard-to-Treat cancers
NCT ID NCT03872778
First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 22 times
Summary
This study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific protein (GRPR). The goal was to see if the drug is safe, how it spreads in the body, and whether it can shrink tumors. Participants received the drug and were monitored for side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Addenbroke's hospital
Cambridge, United Kingdom
-
CHU de Grenoble
La Tronche, France
-
City of Hope
Duarte, California, 91010, United States
-
Erasmus MC
Rotterdam, Netherlands
-
John Hopkins University
Baltimore, Maryland, 21287, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Medical University of Innsbruck
Innsbruck, Austria
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Pittsburgh University
Pittsburgh, Pennsylvania, 15213, United States
-
Stanford University
Stanford, California, 94305, United States
-
Vall d'Hebron Institute of Oncology
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.